Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada
Lisa Maree Williams/Getty Images News The $5 a share contingent value right in Astrazeneca's (NASDAQ:AZN) planned $1.1 billion purchase of Icosavax (NASDAQ:ICVX) is based on FDA approval of RSV vaccine candidate IVX-A12 and some sales…
